Now showing items 1-4 of 4
The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial
Background: The seasonal influenza vaccine is less effective in older people and a single dose is unlikely to provide the year-round protection necessary for tropical climates which have year-round influenza virus activity. ...
Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any ...
Low antibody titers five years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees
Globally, dengue virus (DENV) is one of the most widespread vector-borne viruses. Dengue disease affects populations in endemic areas and, increasingly, tourists who travel to these countries, but there is currently no ...
Moving forward with Takeda's live chimeric tetravalent dengue vaccine
Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly ...